BioMarin Pharmaceutical Inc. completed its previously announced agreement to acquire Alesta Therapeutics, adding ALE1 to its skeletal conditions portfolio.
Public source
Publisher name
Public post
We have completed our previously announced agreement to acquire Alesta Therapeutics. The acquisition will strengthen our skeletal conditions portfolio by adding ALE1, an…
Company
BioMarin Pharmaceutical Inc.
We transform lives through genetic discovery.
- Industry
- Biotechnology Research
- Location
- San Rafael, US
- Company size
- 1,001–5,000 employees
About BioMarin Pharmaceutical Inc.
Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of the genetic conditions that it seeks to treat, helping to better the lives of those struggling with rare genetic disease. BioMarin discoveries have led to eight first or best-in-class commercial treatments and a pipeline of multiple product candidates applying the same science-driven, patient-forward approach to broader group of genetic disorders. The more innovative solutions developed, the more lives BioMarin can impact. Recruitment Fraud Alert Notice Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent BioMarin in recruitment activities. We have an established recruitment process which is required for all posted positions by BioMarin prior to issuing an offer of employment. This BioMarin process requires formal interviews conducted live with personnel representing BioMarin and never requires payments or fees from job applicants. BioMarin does not conduct interviews via texting tools such as RingCentral. In the event you receive a suspicious email message about recruiting on behalf of BioMarin, unless it’s from a BioMarin authorized recruiting partner, do not provide any personal information or pay any fees. Qualified and interested candidates should apply to current openings directly through this BioMarin website. BioMarin accepts no responsibility for any costs or charges incurred as a result of fraudulent activity. If you have lost money or provided your personal identifying information, please contact your bank and report the matter to the FBI via www.ic3.gov. We would also suggest you notify your local police department and monitor your credit. We appreciate your interest in BioMarin & encourage you to visit http://careers.biomarin.com/career-areas to review job opportunities.
See moreLatest activity
Latest activity from BioMarin Pharmaceutical Inc.
6 signals
Presence & Recognition
BioMarin Pharmaceutical Inc. is hosting a series of talks on spectral cytometry and semisupervised immune cluster identification at the Northern California Cytometry Group meeting in a few weeks.
Partnerships
BioMarin Pharmaceutical Inc. is looking forward to a new collaboration with Nucleate to help emerging biotech entrepreneurs navigate the earliest stages of venture creation.
Presence & Recognition
BioMarin Pharmaceutical Inc. employee Fusion 4 Quality John Mulvey was shortlisted for Consultant of the Year – Small at the upcoming 2026 Construction Awards.
Discover more
Similar signals
Similar public activity from other companies.
Strategy & Corporate Development
Apogee Therapeutics
Apogee Therapeutics is now part of AbbVie
Strategy & Corporate Development
Fortrea
Fortrea announced a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials to expand its early clinical development network with dedicated large and small molecule bioanalytical capabilities and increased bedspace capacity.
Strategy & Corporate Development
Alkeus Pharmaceuticals, Inc.
Alkeus Pharmaceuticals, Inc. was acquired by Tarsus Pharmaceuticals, Inc. on September 4.
Strategy & Corporate Development
Merida Biosciences
Merida Biosciences entered into a definitive agreement to be acquired by Eli Lilly and Company to advance treatments for serious autoimmune and allergic diseases.
Strategy & Corporate Development
Korsana Biosciences